AUG 12, 2026 · PHASE 1 TRIAL
A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab
ClinicalTrials.gov
This is a Phase 1 safety and feasibility study of a novel PET imaging agent in a small planned cohort with no results yet reported in the registry record.
Reported
Planned enrollment6
Study phasePhase 1
Primary outcome measure 1Incidence of treatment-related adverse even…